Related Experiment Video

Updated: Mar 22, 2026

Measuring Neural Mechanisms Underlying Sleep-Dependent Memory Consolidation During Naps in Early Childhood
08:20

Measuring Neural Mechanisms Underlying Sleep-Dependent Memory Consolidation During Naps in Early Childhood

Published on: October 2, 2019

12.6K

Parietal Fast Sleep Spindle Density Decrease in Alzheimer's Disease and Amnesic Mild Cognitive Impairment

Maurizio Gorgoni1, Giulia Lauri1, Ilaria Truglia1

  • 1Department of Psychology, "Sapienza" University of Rome, 00185 Rome, Italy.

Neural Plasticity
|April 12, 2016
PubMed

Insights

Alzheimer's disease (AD) and Mild Cognitive Impairment (MCI) patients exhibit reduced fast sleep spindle density in the parietal region. This reduction correlates with cognitive decline severity, suggesting an early, location-specific change in AD.

Area of Science:

  • Neuroscience
  • Sleep Medicine
  • Cognitive Neurology

Background:

  • Sleep spindles, crucial for memory consolidation, manifest as fast (13-15 Hz) centroparietal and slow (11-13 Hz) frontal types.
  • Alterations in sleep spindle activity are linked to Alzheimer's disease (AD) and Mild Cognitive Impairment (MCI).
  • Previous research noted reduced fast spindle counts in AD/MCI, but local specificity and relation to cognitive decline remain unclear, with spindle density unassessed.

Purpose of the Study:

  • To investigate the density of fast and slow sleep spindles in AD and MCI patients.
  • To determine if changes in spindle density are specific to frequency and location (parietal vs. frontal).
  • To explore the relationship between spindle density and cognitive decline severity in AD and MCI.

Main Methods:

  • Assessed fast and slow sleep spindle densities in 15 AD patients, 15 MCI patients, and 15 healthy controls (HC).
  • Utilized polysomnography with 19 cortical derivations during non-rapid eye movement sleep.
  • Employed automatic spindle detection and compared densities at parietal and frontal regions, where fast and slow spindles are maximally expressed.

Main Results:

  • AD and MCI patients demonstrated a significant decrease in parietal fast spindle density compared to HC.
  • This reduction in fast spindle density was positively correlated with Mini-Mental State Examination (MMSE) scores.
  • No significant differences were observed in frontal slow spindle density across groups.

Conclusions:

  • AD-related changes in sleep spindle density are frequency- and location-specific, primarily affecting parietal fast spindles.
  • The observed decrease in fast spindle density is associated with the severity of cognitive impairment.
  • These findings suggest that altered sleep spindle characteristics may represent an early biomarker in the development of Alzheimer's disease.

More Related Videos

A Chronic Sleep Fragmentation Model using Vibrating Orbital Rotor to Induce Cognitive Deficit and Anxiety-Like Behavior in Young Wild-Type Mice06:23

A Chronic Sleep Fragmentation Model using Vibrating Orbital Rotor to Induce Cognitive Deficit and Anxiety-Like Behavior in Young Wild-Type Mice

Published on: September 22, 2020

6.2K
Evaluation of Hemisphere Lateralization with Bilateral Local Field Potential Recording in Secondary Motor Cortex of Mice07:03

Evaluation of Hemisphere Lateralization with Bilateral Local Field Potential Recording in Secondary Motor Cortex of Mice

Published on: July 31, 2019

7.3K

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
2.0K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.2K